Fundraising FoxCOURAGE THERAPEUTICS INC
Newton, US · 2 known investors
Find your way into COURAGE THERAPEUTICS INC
Sign up to find every way you can get introduced to COURAGE THERAPEUTICS INC
- Your email: who you already know at COURAGE THERAPEUTICS INC, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the COURAGE THERAPEUTICS INC team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy. The company translates research on the melanocortin system into therapeutic candidates for patients with MC4R pathway-driven obesity in the US.
Founders & leadership
Board
Investors · 2
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$4.5M disclosed across 1 round · 2025
▶$4.5MraisedMay 2025 · 14 investors · BiotechnologyRule 506(b)
- Isaac BarchasDirector
- Roger ConeDirector
- Bruce LeutcherDirector
- Daniel HousmanExecutive Officer, Director
- Offering amount
- $10.5M
- Amount sold
- $4.5M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $250.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $244.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does COURAGE THERAPEUTICS INC do?
- Courage Therapeutics is a neuroendocrine biotech developing MC4R agonist drugs for genetic obesity; its lead candidate CTX-B is a weekly injectable targeting melanocortin-4 receptor haploinsufficiency (MC4R HI), a form of early-onset severe obesity with no approved targeted therapy. The company translates research on the melanocortin system into therapeutic candidates for patients with MC4R pathway-driven obesity in the US.
- Who founded COURAGE THERAPEUTICS INC?
- COURAGE THERAPEUTICS INC was founded by Roger Cone, Dan Housman.
- Who are COURAGE THERAPEUTICS INC's investors?
- COURAGE THERAPEUTICS INC's investors include Arsenal Bridge Venture, Augment Ventures.
- How much funding has COURAGE THERAPEUTICS INC raised?
- COURAGE THERAPEUTICS INC has disclosed $4.5M raised across 1 round.
- Where is COURAGE THERAPEUTICS INC headquartered?
- COURAGE THERAPEUTICS INC is headquartered in Newton, US.